FDA approves Regeneron’s Eylea HD for extended five-month dosing interval

The US FDA approved an extended dosing interval for Eylea HD (aflibercept), allowing Regeneron Pharmaceuticals to label the 8 mg intravitreal injection for dosing intervals of up to five months in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). The company said this makes Eylea HD the first injectable anti-VEGF agent with a labelled interval of up to 20 weeks for both conditions, representing a label update to a product originally cleared by the US FDA in August 2023.

The April 2026 approval specifically extends the maximum dosing interval beyond the 8-16 week range established at the time of the original approval. Under the updated label, patients with wAMD or DME who have completed one year of treatment may be eligible for the extended schedule. The formulation is a higher-concentration version of the established aflibercept molecule, delivered as an intravitreal injection, and developed in the US by Regeneron under its longstanding ophthalmic collaboration with Bayer, which retains commercialization rights outside the United States.

The regulatory decision drew on 96-week data from two randomized, double-masked, non-inferiority pivotal trials: PULSAR, which enrolled patients with wAMD, and PHOTON, which enrolled patients with DME. Both studies compared aflibercept 8 mg against the established 2 mg dose of the same molecule. Published 48-week readouts, available via AllSci and PubMed, showed that visual acuity outcomes with the 8 mg formulation were non-inferior to those with the 2 mg reference dose at that timepoint. The company said the majority of patients in both trials maintained their visual and anatomic improvements when transitioned to extended dosing intervals over the full 96-week period, though the approval announcement did not disclose full 96-week efficacy tables or detailed safety breakdowns..

The approval lands in a retinal treatment field where the frequency of intravitreal injection has been a persistent clinical and practical concern. Anti-VEGF therapy transformed the management of wAMD and DME from the mid-2000s onward, converting conditions that frequently caused severe vision loss into ones where stabilization and, in many cases, functional improvement are achievable. Yet the injection burden associated with monthly or bimonthly dosing has long been identified as a factor in suboptimal real-world adherence, with patients and clinicians alike seeking regimens that reduce clinic visits without sacrificing disease control.

Eylea HD joins a field that has already been moving toward extended durability as a central differentiating axis. Genentech’s faricimab (Vabysmo), approved in January 2022 for both wAMD and DME, introduced a bispecific mechanism targeting both VEGF-A and Angiopoietin-2, and carried labelling permitting up to 16-week dosing intervals from the outset of maintenance therapy. Genentech’s ranibizumab port delivery system, Susvimo, received US FDA approval for DME in February 2025, offering a surgically implanted refillable device that delivers continuous anti-VEGF exposure and requires refilling approximately every six months. The Eylea HD label update, at up to 20 weeks for eligible patients, extends the injectable interval further than any previously approved intravitreal anti-VEGF injection, as noted in the company’s announcement.

The competitive context also includes an expanding biosimilar landscape for the original 2 mg aflibercept formulation, with Sandoz’s aflibercept-abzv (Enzeevu) receiving US FDA approval as an interchangeable biosimilar in August 2024. That dynamic adds complexity to Regeneron’s positioning of the higher-dose product, as cost-driven substitution of the reference 2 mg product becomes more feasible in parallel with the clinical case for the 8 mg formulation’s durability profile.

Aflibercept itself is a fusion protein constructed from domains of VEGF receptor 1 and VEGF receptor 2 linked to an IgG1 Fc region, acting as a decoy receptor that sequesters VEGF-A, VEGF-B, and placental growth factor. Regeneron invented the molecule internally using its VelociSuite platform and has retained exclusive US commercialisation rights for the ophthalmic formulation throughout the product’s development history. The broader aflibercept franchise, including the original Eylea 2 mg product approved in 2011, has been one of Regeneron’s principal revenue sources for over a decade.